drugset
drugset / Trial / NCT06024915

A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets

NCT06024915 ↗

Phase 1 Completed 40 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a single-center, open, single-dose, self-controlled phase I clinical trial to evaluate the effects of metabolic enzyme inhibitors/inducers on in vivo metabolic and elimination of TQ05105 tablets, and the safety of metabolic enzyme inhibitors/inducers combined with TQ05105 tablets.

Timeline

Start
2023-09-21
Primary completion
2024-01-29
Completion
2024-05-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Itraconazole Small molecule 0.2 g —
Subject Rifampin Small molecule 0.6 g —
Subject TQ05105 Small molecule — Oral

Indications

myelofibrosis